menu
    • menu
    [{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"AIGH Capital Management | Soleus Capital | Nantahala Capital | Diadema Partners | Stonepine Capital Management | ADAR1 Capital Management | Velan Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Dipalmitoyl hydroxyproline","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.10000000000000001,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ AIGH Capital Management | Soleus Capital | Nantahala Capital | Diadema Partners | Stonepine Capital Management | ADAR1 Capital Management | Velan Capital","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ AIGH Capital Management | Soleus Capital | Nantahala Capital | Diadema Partners | Stonepine Capital Management | ADAR1 Capital Management | Velan Capital"}]

    Find Clinical Drug Pipeline Developments & Deals for Dipalmitoyl hydroxyproline

    Menu

    Dipalmitoyl hydroxyproline

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quoin Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Quoin Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipalmitoyl hydroxyproline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : AIGH Capital Management | Soleus Capital | Nantahala Capital | Diadema Partners | Stonepine Capital Management | ADAR1 Capital Management | Velan Capital

                            Deal Size : $104.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Quoin Pharmaceuticals Announces $104.5M Private Placement Financing

                            Details : The proceeds from the offering will used to fund the clinical development of Dipalmitoyl Hydroxyproline for Netherton Syndrome.

                            Product Name : QRX003

                            Product Type : Miscellaneous

                            Upfront Cash : $16.5 million

                            October 10, 2025

                            Lead Product(s) : Dipalmitoyl hydroxyproline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : AIGH Capital Management | Soleus Capital | Nantahala Capital | Diadema Partners | Stonepine Capital Management | ADAR1 Capital Management | Velan Capital

                            Deal Size : $104.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth